About: Tocilizumab in patients with severe COVID‐19: a single‐center observational analysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Tocilizumab in patients with severe COVID‐19: a single‐center observational analysis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Tocilizumab in patients with severe COVID‐19: a single‐center observational analysis
Creator	Colomy, Veronika Einstein, Pharmd Knorr, John Mauriello, Christine Network, Healthcare Road, Old
topic	covid:4902b025f07a44ca02aae3916cf045768b51eb32#this
source	Medline; PMC
abstract	OBJECTIVE: Patients with coronavirus disease 2019 (COVID‐19) may develop severe respiratory distress, thought to be mediated by cytokine release. Elevated proinflammatory markers have been associated with disease severity. Tocilizumab, an IL‐6 receptor antagonist, may be beneficial for severe COVID‐19, when cytokine storm is suspected. METHODS: This is a retrospective single‐center analysis of the records of patients diagnosed with COVID‐19 who received tocilizumab. Outcomes, including clinical improvement, mortality and changes in oxygen‐support at 24, 48, and 72 hours, and 7, 14 and 28 days post‐tocilizumab, are reported. Patients were evaluated by baseline pre‐tocilizumab oxygenation status and changes in proinflammatory markers within seven days post‐tocilizumab are reported. RESULTS: Sixty‐six patients received tocilizumab at a mean dose of 724mg (7.4mg/kg), 3.7 days from admission. At baseline, 53% of patients were on ventilation support and all had elevated proinflammatory markers, including c‐reactive protein (CRP). Common comorbidities were diabetes mellitus (43%) and hypertension (74%). Most patients received concomitant glucocorticoids and hydroxychloroquine. Seven days after tocilizumab, ten patients (15.2%) had clinical improvement in their oxygenation status, and there was a 95% decrease in CRP. Within 14 days of treatment, 29% of patients had clinical improvement, 20% had minimal or no improvement, 17% worsened, 27% died, and 7% were transferred to an outside hospital. Ultimately, 42% of all patients that received tocilizumab expired and 49% were discharged. CONCLUSION: This study found limited clinical improvement in patients that received tocilizumab in the setting of severe COVID‐19. Clinical trials are ongoing to further evaluate tocilizumab's benefit in this patient population. This article is protected by copyright. All rights reserved.
has issue date	2020-06-17(xsd:dateTime)
bibo:doi	10.1002/jmv.26191
bibo:pmid	32628003
has license	no-cc
sha1sum (hex)	4902b025f07a44ca02aae3916cf045768b51eb32
schema:url	https://doi.org/10.1002/jmv.26191
resource representing a document's title	Tocilizumab in patients with severe COVID‐19: a single‐center observational analysis
has PubMed Central identifier	PMC7323415
has PubMed identifier	32628003
schema:publication	J Med Virol
resource representing a document's body	covid:4902b025f07a44ca02aae3916cf045768b51eb32#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/4902b025f07a44ca02aae3916cf045768b51eb32
is schema:about of	named entity 'cytokine storm' named entity 'COVID-19' named entity 'ELEVATED' named entity 'beneficial' named entity 'IL-6 receptor' named entity 'Elevated' named entity 'ferritin' named entity 'Tocilizumab' named entity 'patients' named entity 'antagonist' named entity 'COVID-19' named entity 'ordinal scale' named entity 'tocilizumab' named entity 'CRP' named entity 'COVID' named entity 'hydroxychloroquine' named entity 'IL-6' named entity 'COVID-19 disease' named entity 'inflammatory markers' named entity 'administered intravenously' named entity 'sodium chloride solution' named entity 'hydroxychloroquine' named entity 'extracorporeal membrane oxygenation' named entity 'Tocilizumab' named entity 'infection' named entity 'glucocorticoids' named entity 'Einstein Medical Center Elkins Park' named entity 'infection' named entity 'COVID-19' named entity 'COPD' named entity 'Einstein Medical Center Philadelphia' named entity 'WHO' named entity 'D-dimer' named entity 'tocilizumab' named entity 'normal range' named entity 'COVID-19' named entity 'D-dimer' named entity 'hypertension' named entity 'invasive ventilation' named entity 'p-values' named entity 'COVID' named entity 'COVID-19' named entity 'Tocilizumab' named entity 'tocilizumab' named entity 'intensive care unit' named entity '28 days' named entity 'COVID' named entity 'randomized studies' named entity 'inflammatory marker' named entity 'ICU' named entity 'selection bias' named entity 'interstitial pneumonitis' named entity 'tocilizumab' named entity 'tocilizumab' named entity 'COVID' named entity 'United States' named entity 'oxygen support' named entity 'COVID' named entity 'hypertension' named entity 'invasive ventilation' named entity 'tocilizumab' named entity 'tocilizumab' named entity 'COVID-19' named entity 'statistically significant' named entity 'COVID-19' named entity 'GraphPad Prism' named entity 'CRP' named entity 'treatment protocol' named entity 'D-dimer' named entity 'tocilizumab' named entity 'tocilizumab' named entity 'thrombotic events' named entity 'IL-6' named entity 'follow-up'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software